Skip to main content
Equibles

Gregory Glenn

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Gregory Glenn

Novavax Inc reported in an 8-K filed March 22, 2023 that Gregory Glenn retired as President, Research and Development, effective March 31, 2023. Novavax Inc reported in an 8-K filed March 2, 2023 that Gregory Glenn retired as President, Research and Development, effective March 31, 2023. The proxy statement of Novavax Inc reports total compensation of $4,093,686 for Gregory Glenn in fiscal 2022, including a base salary of $593,750. Disclosed compensation is on record for 6 fiscal years.

“on February 28, 2023, Dr. Gregory M. Glenn, M.D. notified Novavax Inc. (the “Company”) of his decision to retire as President, Research and Development, effective as of March 31, 2023.”
Novavax Inc Form 8-K, filed March 22, 2023 · Read the filing
“On February 28, 2023, Dr. Gregory M. Glenn, M.D. notified Novavax Inc. (the "Company") of his decision to retire as President, Research and Development, effective as of March 31, 2023.”
Novavax Inc Form 8-K, filed March 2, 2023 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2022 Novavax Inc (NVAX) $593,750 $4,093,686
2021 Novavax Inc (NVAX) $553,000 $813,444
2020 Novavax Inc (NVAX) $483,443 $24,923,376
2019 Novavax Inc (NVAX) $470,453 $1,875,198
2018 Novavax Inc (NVAX) $460,125 $1,681,456
2017 Novavax Inc (NVAX) $450,000 $1,221,250

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.